President Donald Trump announced the launch of a new government website designed to help Americans access cheaper prescription medications. Speaking at a White House event alongside Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, and Joe Gebbia, co-founder of Airbnb, Trump promised that people will "save a lot of money and be healthy," according to Reuters.
But here's the catch: TrumpRx.gov won't actually fill your prescriptions. Instead, the site functions as a price comparison and coupon platform. Consumers can search for their medications, view discounted prices available through agreements with drugmakers, and then print a coupon to redeem at participating pharmacies or directly through manufacturers' websites.
The Drugmaker Deals
Trump has secured "most-favored-nation" pricing deals with five major pharmaceutical companies, bringing 40 medications to the platform at launch. The participating companies are AstraZeneca PLC (AZN), Eli Lilly And Co. (LLY), EMD Serono, Novo Nordisk (NVO), and Pfizer Inc. (PFE).
The price cuts are substantial in some cases. Ozempic and Wegovy, widely used medications for diabetes and obesity, currently cost $1,028 and $1,349 per month respectively. Under the new program, those prices could drop to as low as $199, depending on dosage. Fertility treatments like Gonal-F and Cetrotide will also see significant reductions.
According to a White House fact sheet, additional drugmakers that have signed MFN pricing agreements will be added to the website in the "coming months," expanding the selection of discounted medications.
Broader Push For Price Transparency
The TrumpRx launch is part of a wider administration effort to tackle prescription drug costs. The Department of Labor has proposed new regulations that would require Pharmacy Benefit Managers (PBMs) to disclose their compensation arrangements to self-insured group health plans, which cover approximately 90 million Americans.
These initiatives represent the administration's ongoing attempt to align U.S. drug prices with international standards. Federal health officials are proposing various models aimed at narrowing the substantial gap between what Americans pay for medications versus what consumers in other countries pay for the same drugs.
